20 completed. 20 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 20 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Hypopharyngeal Neoplasms: new trials by email Literature Review of Hypopharyngeal Neoplasms trials Research Report on Hypopharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy - Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Completed | Hyunseok Kang, MD | 16 | 2020-10-14 | 2024-06-28 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Pembrolizumab, Cetuximab - HNSCC, Lip SCC | Phase 2 | Completed | University of California, San Diego | 78 | 2017-03-28 | 2026-10-01 |
| Adaptive Radiotherapy for Head and Neck Cancer Adaptive Radiotherapy - Head and Neck Cancer, Paranasal Sinus Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 64 | 2017-03-15 | 2021-10-26 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Cetuximab - Oropharyngeal Cancer, Hypopharyngeal Cancer | Phase 2 | Completed | University of Zurich | 68 | 2011-09-19 | 2017-11-06 |
| Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) neoadjuvant docetaxel/cisplatin/fluorouracil, No treatment before definitive CCRT - Hypopharyngeal Cancer | Phase 2 | Completed | Samsung Medical Center | 40 | 2010-11-01 | 2019-12-09 |
| Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer cetuximab, cisplatin, intensity-modulated radiation therapy - Head and Neck Cancer | Phase 2 | Completed | University of Texas Southwestern Medical Center | 37 | 2008-12-01 | 2020-08-21 |
| Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Pilocarpine, ALTENS - Head and Neck Cancer, Xerostomia | Phase 2 / Phase 3 | Completed | Radiation Therapy Oncology Group | 196 | 2008-09-01 | 2019-11-19 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. placebo, laboratory biomarker analysis, questionnaire administration - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 70 | 2007-09-04 | 2020-02-20 |
| Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract cetuximab - Head and Neck Cancer, Precancerous Condition | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 35 | 2007-05-01 | 2020-03-12 |
| Bupropion in Helping Adults Stop Smoking bupropion hydrochloride, placebo - Bladder Cancer, Cervical Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 95 | 2006-01-01 | 2017-05-30 |
| Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation cetuximab, Cisplatin, Radiotherapy 70 Gy, 35 fractions - Larynx Cancer, Hypopharynx Cancer | Phase 2 | Completed | Groupe Oncologie Radiotherapie Tete et Cou | 156 | 2005-10-01 | 2011-06-27 |
| Zinc Supplements in Lowering Cadmium Levels in Smokers zinc oxide - Bladder Cancer, Cervical Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 61 | 2003-12-01 | 2017-05-30 |
| Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia celecoxib - Head and Neck Cancer, Precancerous Condition | Phase 2 | Completed | Fox Chase Cancer Center | 2003-11-01 | 2013-07-11 | |
| Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Celecoxib - Head and Neck Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 23 | 2002-06-01 | 2018-03-29 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer ethynyluracil, fluorouracil, hydroxyurea - Head and Neck Cancer | Phase 1 / Phase 2 | Completed | Robert H. Lurie Cancer Center | 1999-10-01 | 2013-06-26 | |
| Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID), Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID), CDDP, 5 Fu - Oropharynx Cancer, Oral Cancer | Phase 2 / Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 120 | 1996-07-01 | 2026-08-19 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer fluorouracil, hydroxyurea, surgical procedure - Esophageal Cancer, Head and Neck Cancer | Phase 2 | Completed | University of Chicago | 53 | 1996-06-01 | 2013-09-05 |
| Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer porfimer sodium, fluorophotometry - Head and Neck Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 1995-02-01 | 2013-02-05 |
Laryngeal Neoplasms (17) · Mouth Neoplasms (16) · Oropharyngeal Neoplasms (16) · Head and Neck Neoplasms (13) · Nasopharyngeal Neoplasms (11) · Tongue Neoplasms (6) · Salivary Gland Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Esophageal Neoplasms (3) · Pancreatic Neoplasms (3) · Carcinoma (2) · Carcinoma, Hepatocellular (2)
Neoplasms (20) · Neoplasms by Site (20) · Otorhinolaryngologic Diseases (20) · Otorhinolaryngologic Neoplasms (20) · Pharyngeal Diseases (20) · Pharyngeal Neoplasms (20) · Stomatognathic Diseases (20) · Laryngeal Diseases (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Mouth Diseases (16) · Nasopharyngeal Diseases (11) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Carcinoma (8)
Cetuximab (6) · Cisplatin (3) · Fluorouracil (3) · Radiotherapy (3) · Celecoxib (2) · Hydroxyurea (2) · Radiotherapy, Intensity-Modulated (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Bupropion (1) · CF regimen (1) · Chemoprevention (1) · Dihematoporphyrin Ether (1) · Disulfides (1)
Roswell Park Cancer Institute (2) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hyunseok Kang, MD (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Radiation Therapy Oncology Group (1) · Robert H. Lurie Cancer Center (1) · Samsung Medical Center (1) · Sanjiv Sam Gambhir (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of California, San Diego (1)
United States (16) · Canada (3) · France (2) · South Korea (1) · Switzerland (1)
Everett E. Vokes, MD (2) · Amit Agrawal (1) · Assuntina Sacco, M.D. (1) · C. Jillian Tsai, MD (1) · Gary G. Schwartz, MD, PhD, MPH (1) · Hyunseok Kang, MD (1) · Jacques Tortochaux (1) · Jean Bourhis (1) · Jean-Louis Lefebvre (1) · Joseph Califano, MD (1) · Loren K Mell (1) · Lori J. Wirth, MD (1) · Martin Mahoney, MD (1) · Michel Lapeyre (1) · Oliver Riesterer, Leitender Arzt (1)
PMID 16849759, PMID 21831465, PMID 22252927, PMID 23341517, PMID 25965900, PMID 26062933, PMID 26611425, PMID 29346519, PMID 30850872, PMID 31705729, PMID 33989559, PMID 39551064
P30CA006516 (1), P30CA006973 (1), P50CA096784 (1), U10CA180868 (1)